Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Brian L. Dake"'
Autor:
Eric P. Davidson, Lawrence J. Coppey, Amey Holmes, Sergey Lupachyk, Brian L. Dake, Christine L. Oltman, Richard G. Peterson, Mark A. Yorek
Publikováno v:
Journal of Diabetes Research, Vol 2014 (2014)
Recently a new rat model for type 2 diabetes the Zucker diabetic Sprague-Dawley (ZDSD/Pco) was created. In this study we sought to characterize the development of diabetic neuropathy in ZDSD rats using age-matched Sprague-Dawley rats as a control. Ra
Externí odkaz:
https://doaj.org/article/1ecf2629e59b4ff0af1f668cc1bc67fe
Autor:
Brian D Fink, Yunxia O'Malley, Brian L Dake, Nicolette C Ross, Thomas E Prisinzano, William I Sivitz
Publikováno v:
PLoS ONE, Vol 4, Iss 1, p e4250 (2009)
Previously, we reported that the "antioxidant" compound "mitoQ" (mitochondrial-targeted ubiquinol/ubiquinone) actually increased superoxide production by bovine aortic endothelial (BAE) cell mitochondria incubated with complex I but not complex II su
Externí odkaz:
https://doaj.org/article/770b3a928ff743819462d9ac36e9677c
Autor:
Brian L. Dake, Christine L. Oltman
Publikováno v:
Obesity. 23:623-629
Objective Obesity is a global epidemic leading to several comorbidities including diabetes and cardiovascular disease. The hypothesis that the genetic background of the obesity-prone rat (OP) predisposes to physiologic, metabolic, and microvascular d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8ba1f4876e4d8fdb81755e6c0fded80
https://doi.org/10.1002/oby.21009
https://doi.org/10.1002/oby.21009
Publikováno v:
European Journal of Pharmacology. 668:497-506
We have previously shown that treating streptozotocin-induced diabetic rats, an animal model of type 1 diabetes, with Ilepatril (an inhibitor of neutral endopeptidase and angiotensin converting enzyme (ACE)) improves vascular and neural functions. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e677577172d11e61bdfb4cf7771a0bd3
https://doi.org/10.1016/j.ejphar.2011.07.016
https://doi.org/10.1016/j.ejphar.2011.07.016
Autor:
Christine L. Oltman, Travis L. Kleinschmidt, Eric P. Davidson, Brian L. Dake, Lawrence J. Coppey, Mark A. Yorek
Publikováno v:
European Journal of Pharmacology. 650:556-562
We have previously shown that treating streptozotocin-induced diabetic rats, an animal model of type 1 diabetes, with Ilepatril (an inhibitor of neutral endopeptidase and angiotensin converting enzyme (ACE)) improves vascular and neural function. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::829fb360dda4a62b145c56c497e79155
https://doi.org/10.1016/j.ejphar.2010.10.047
https://doi.org/10.1016/j.ejphar.2010.10.047
Publikováno v:
Hypertension. 66
Neurogenic mechanisms play a major role in obesity-induced increase in sympathetic nerve activity (SNA) and arterial pressure, but the molecular pathways involved remain ill defined. Mechanistic target of rapamycin complex 1 (mTORC1) signaling in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0413e39eaf60b4745ff2ad79eb649ae
https://doi.org/10.1161/hyp.66.suppl_1.p237
https://doi.org/10.1161/hyp.66.suppl_1.p237
Publikováno v:
Endocrinology. 145:3369-3374
A fusion protein, FP 6/3, composed of IGF binding protein (IGFBP)-6 and IGFBP-3 was synthesized where the complete sequences of each binding protein were fused together into a single chimeric protein. The orientation of this fusion protein's structur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaa00fd3a935f3160eaf5cee2aafd413
https://doi.org/10.1210/en.2003-1667
https://doi.org/10.1210/en.2003-1667
Autor:
Alexander Sandra, M Bateman, Brian L. Dake, Robert S. Bar, Mary Boes, Kevin L. Knudtson, Barbara A. Booth
Publikováno v:
Growth Hormone & IGF Research. 12:91-98
Insulin-like growth factor binding protein 6 (IGFBP-6) is a high-affinity IGFBP with substantially greater affinity for insulin-like growth factor-II (IGF-II) than IGF-I. IGFBP-6(3) is a chimera which has a 20 amino acidC -terminal portion of IGFBP-6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66e5041f98e4941576cfda38f6d6811d
https://doi.org/10.1054/ghir.2001.0266
https://doi.org/10.1054/ghir.2001.0266
Autor:
Brian L. Dake, Sergey Lupachyk, Richard G. Peterson, Christine L. Oltman, Lawrence J. Coppey, Mark A. Yorek, Amey Holmes, Eric P. Davidson
Publikováno v:
Journal of Diabetes Research
Journal of Diabetes Research, Vol 2014 (2014)
Journal of Diabetes Research, Vol 2014 (2014)
Recently a new rat model for type 2 diabetes the Zucker diabetic Sprague-Dawley (ZDSD/Pco) was created. In this study we sought to characterize the development of diabetic neuropathy in ZDSD rats using age-matched Sprague-Dawley rats as a control. Ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40f1644ba7c16e7308f3a04292988d0a
http://europepmc.org/articles/PMC4211210
http://europepmc.org/articles/PMC4211210
Autor:
Brian L, Dake, Christine L, Oltman
Publikováno v:
Obesity (Silver Spring, Md.). 23(3)
Obesity is a global epidemic leading to several comorbidities including diabetes and cardiovascular disease. The hypothesis that the genetic background of the obesity-prone rat (OP) predisposes to physiologic, metabolic, and microvascular dysfunction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3fcc009d1bd8b17410bd016073c3d0b0
https://pubmed.ncbi.nlm.nih.gov/25645537
https://pubmed.ncbi.nlm.nih.gov/25645537